Skip to main content

Table 1 Clinical prognostic features of HGSC patients

From: Characterization of ovarian clear cell carcinoma using target drug-based molecular biomarkers: implications for personalized cancer therapy

Prognostic factors Cases (%) Univariate Pa Multivariate
HR (95% CI) Pb
Age (years)   0.281   0.495
  ≤ 57 (median) 57(50.4)   1.000  
  > 57 (median) 56(49.6)   1.010(0.982–1.037)  
FIGO Stage   0.002   0.047
 Early(I + II) 17(15.0)   1.000  
 Late(III + IV) 96(85.0)   3.241(1.065–10.879)  
Residual tumor (cm)   0.042   0.543
  ≤ 1 104(92.0)   1.000  
  > 1 9(8.0)   1.300 (0.558–3.027)  
Ascites   0.085   0.690
 No 11(9.7)   1.000  
 Yes 102(90.3)   1.280(0.380–4.311)  
Endometriosis   0.140   0.568
 No 101(89.4)   1.000  
 Yes 12(10.6)   1.245(0.586–2.647)  
Chemotherapeutic response   0.000   0.000
 Platinum sensitive 77(72.0)   1.000  
 Platinum resistant 30(28.0)   3.573(2.056–6.210)  
  1. Log rank test
  2. awithout adjustment
  3. Cox proportional hazards regression analysis
  4. bwith adjustment for age, FIGO stage, residual tumor, ascites, endometriosis, and chemotherapeutic response
  5. Bold value denotes P with statistical significance